Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines

Vaccine

Volumn 31, Issue 42, 2013, Pages 4827-4833

  Tontini, M ^a   Berti, F ^a   Romano, M R ^a   Proietti, D ^a   Zambonelli, C ^a   Bottomley, M J ^a   De Gregorio, E ^a   Del Giudice, G ^a   Rappuoli, R ^a   Costantino, P ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Carrier priming; Conjugate vaccines; CRM197; Diphtheria toxoid; Meningococcal vaccines; Tetanus toxoid

Indexed keywords

CARBOHYDRATE; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID CRM197; MENINGOCOCCUS VACCINE; OLIGOSACCHARIDE; TETANUS TOXOID; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); DRUG CARRIER; VACCINE; CRM197 (NON TOXIC VARIANT OF DIPHTHERIA TOXIN);

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; NEISSERIA MENINGITIDIS; CARRIER PRIMING; CONJUGATE VACCINES; CRM(197);

ANIMALS; BACTERIAL PROTEINS; DIPHTHERIA TOXOID; DRUG CARRIERS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINES, CONJUGATE;

CARRIER PRIMING; CONJUGATE VACCINES; CRM(197); DIPHTHERIA TOXOID; MENINGOCOCCAL VACCINES; TETANUS TOXOID;

EID: 84884204137     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.078     Document Type: Article

References (41)

1. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(Suppl.):B26-B36.
2. Harrison L.H., Pelton S.I., Wilder-Smith A., Holst J., Safadi M.A., Vazquez J.A., et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011, 29:3363-3371.
3. Chang Q., Tzeng Y.L., Stephens D.S. Meningococcal disease: changes in epidemiology and prevention. Clinical Epidemiology 2012, 4:237-245.
4. Schneerson R., Robbins J.E., Chu C.Y., Sutton A., Schiffman G., Vann W.F. Semi-synthetic vaccines composed of capsular polysaccharides of pathogenic bacteria covalently bound to proteins for the prevention of invasive diseases. Progress in Allergy 1983, 33:144-158.
5. Kelly D.F. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. The Journal of the American Medical Association 2005, 294:3019-3023.
6. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nature Reviews Drug Discovery 2010, 9:308-323.
7. Costantino P., Rappuoli R., Berti F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opinion on Drug Discovery 2011, 6:1045-1066.
8. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(Suppl.):B30-B41.
9. Dbaibo G., Macalalad N., Reyes MRA-DL, Dimaano E., Bianco V., Baine Y., et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Human Vaccines and Immunotherapeutics 2012, 8(7):873-880.
10. Zou W., Jennings H.J. Preparation of glycoconjugate vaccines. Carbohydrate-Based vaccines and immunotherapies 2008, 55-88. John Wiley & Sons, Inc., Hoboken, NJ, USA. Z. Guo, G.J. Boons (Eds.).
11. Bröker M., Dull P.M., Rappuoli R., Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009, 27:5574-5580.
12. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985, 150:76-85.
13. Bardotti A., Averani G., Berti F., Berti S., Carinci V., D'Ascenzi S., et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 2008, 26:2284-2296.
14. Ricci S., Bardotti A., D'Ascenzi S., Ravenscroft N. Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection. Vaccine 2001, 19:1989-1997.
15. Giuliani M.M., Santini L., Brunelli B., Biolchi A., Aricò B., Di Marcello F., et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infection and Immunity 2005, 73:1151-1160.
16. Rappuoli R. New and improved vaccines against diphtheria and tetanus. New Generation Vaccines 1997, 417-436. Marcel Dekker, New York. 2nd ed. Revised and Expanded. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
17. Romero Méndez Y.A., Shi Y., HogenEsch H., Hem S.H. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007, 25:825-833.
18. Granoff D.M., Holmes S.J., Belshe R.B., Osterholm M.T., McHugh J.E., Anderson E.L. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. The Journal of the American Medical Association 1994, 272:1116-1121.
19. Granoff D.M., Rathore M.H., Holmes S.J., Granoff P.D., Lucas A.H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993, 11(Suppl. 1):S46-S51.
20. Shelly M.A., Pichichero M.E., Treanor J.J. Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccines in adults. Scandinavian Journal of Infectious Diseases 2001, 33(7):542-544.
21. Barington T., Skettrup M., Juul L., Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infection and Immunity 1993, 61:432-438.
22. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infection and Immunity 2002, 70(9):4946-4954.
23. Lee L.H., Blake M.S. Effect of increased CRM197 carrier protein dose on meningococcal C bactericidal antibody response. Clinical and Vaccine Immunology 2012, 19:551-556.
24. Dagan R., Goldblatt D., Maleckar J.R., Yaïch M., Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infection and Immunity 2004, 72:5383-5391.
25. Borrow R., Dagan R., Zepp F., Hallander H., Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Review of Vaccines 2011, 10:1621-1631.
26. Knuf M., Kowalzik F., Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011, 29:4881-4890.
27. Usonis V., Bakasenas V., Lockhart S., Baker S., Gruber W., Laudat F. A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine. Vaccine 2008, 26:4602-4607.
28. Ruiz-Palacios G.M., Huang L-M., Lin T-Y., Hernandez L., Guerrero M.L., Villalobos A.L., et al. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus Influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. The Pediatric Infectious Disease Journal 2013, 32:62-71.
29. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infection and Immunity 1991, 59:3504-3510.
30. Avci F.Y., Li X., Tsuji M., Kasper D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nature Medicine 2011, 17:1602-1609.
31. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research 1984, 12:4063-4069.
32. Dagan R., Poolman J., Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
33. Herzenberg L.A., Tokuhisa T. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. The Journal of Experimental Medicine 1982, 155:1730-1740.
34. Schutze M.P., Deriaud E., Przewlocki G., LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. The Journal of Immunology 1989, 142:2635-2640.
35. Herzenberg L.A., Tokuhisa T., Parks D.R., Herzenberg L.A. Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory. The Journal of Experimental Medicine 1982, 155:1741-1753.
36. LeClerc C., Schutze M.P., Deriaud E., Przewlocki G. The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression. The Journal of Immunology 1990, 145:1343-1349.
37. Bröker M., Costantino P., DeTora L., McIntosh E.D., Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011, 39:195-204.
38. Malito E., Bursulaya B., Chen C., Lo Surdo P., Picchianti M., Balducci E., et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proceedings of the National Academy of Sciences of the United States 2012, 109:5229-5234.
39. Dagan R., Eskola J., LeClerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infection and Immunity 1998, 66:2093-2098.
40. Prymula R., Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Review of Vaccines 2009, 8:1479-1500.
41. Ihssen J., Kowarik M., Dilettoso S., Tanner C., Wacker M., Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microbial Cell Factories 2010, 9:61.